Navigation Links
CEL-SCI Corporation Releases Letter to Shareholders
Date:7/7/2009

e III endpoint is substantially smaller than the 33% increase seen in Phase II.
  • No toxicity issues have been identified.
  • No safety issues have been identified.
  • Clear unmet medical need.
  • FDA granted Multikine Orphan Drug status in the USA.

  • Our clinical success would be huge since Multikine would be on course to become the recommended first-line treatment for head and neck cancer. From there, we could hopefully prove that Multikine is likely to work against other solid tumors as well.

    Our ultimate goal in development is to provide patients and physicians with a new and better way of fighting cancer. We believe that the key to doing so lies in our immune system. Dendreon's prostate cancer vaccine recently established that this is possible. Their success is even more impressive because they focused on late-stage cancer patients. We believe that Multikine should have an even greater chance of success because we focus on patients not yet treated for their cancer. Their immune system is still intact, except in the area of the tumor, and their lymphatics have not yet been cut, meaning that they can still deliver immune cells from the local lymph nodes to the tumor.

    From here on there is only one thing to do. We will launch the Phase III study as quickly as possible. Success would be phenomenal, and we anticipate that it should enable rapid approval around the world.

    We thank you for your continued support.

    Sincerely,

    Geert Kersten

    Chief Executive Officer

    When used in this report, the words "intends," "believes," "anticipated" and "expects" and similar expressions are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties which could cause actual results to differ materially from those projected.
    '/>"/>

    SOURCE CEL-SCI Corporation
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related biology technology :

    1. CEL-SCI to Present at the Noble Financial Conference
    2. CEL-SCI CORPORATION Manufacturing Facility for Pivotal Phase III Cancer Trial Scheduled to Be Completed During 2008 Third Quarter
    3. CEL-SCI Announces Exclusive Licensing Agreement with Teva for Cancer Drug Multikine
    4. CEL-SCI CORPORATION Reports Third Quarter 2008 Financial Results
    5. CEL-SCI Takes Delivery of New Manufacturing Facility
    6. Updated Pictures of CEL-SCI Manufacturing Facility Available Online
    7. CEL-SCI Corporation Releases Letter to Shareholders
    8. CEL-SCI Corporation Announces 2008 Financial Results
    9. CEL-SCI Corporation to Launch Aseptic Filling for Stem Cell Produced Therapies and Other Biological Products
    10. CEL-SCI Presents Data at Prestigious Medical Conference Demonstrating That Its L.E.A.P.S. Technology Stimulates Maturation of Human Blood Cells Into Dendritic Cells Suggesting Potential for Prevention and Treatment of Infectious Disease
    11. CEL-SCIs L.E.A.P.S. Technology Shows Potential to Treat Swine Influenza in Preclinical Studies
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:3/31/2015)... N.J. , March 31, 2015  Bayer ... Broad Institute of Massachusetts Institute of Technology (MIT) ... drug discovery. The goal of this new part ... human genetics to help create new cardiovascular therapies. ... collaboration with the Broad Institute to the area ...
    (Date:3/31/2015)... This June 13th, a distinguished group ... and International Medical Schools will come together in Santa ... application of stem cell therapy in treatments and cures ... funded by the Ocular Research Symposia Foundation, Inc. ... intimate meetings of top experts in the field of ...
    (Date:3/30/2015)... 30, 2015 PMG Research, Benchmark ... announce the formation of VaxCorps, a network of ... in the conduct of vaccine trials in healthy ... sites have successfully conducted over 500 phase I-III ... and pandemic influenza as well as a vast ...
    (Date:3/30/2015)... 2015 US-Australian drug discovery company, Novogen Ltd, ... Inc., and Yale University, on March 27 released pre-clinical ... presented as an oral presentation by Professor Gil ... the 62 nd Annual Scientific Meeting of the ... CA. In both in vitro ...
    Breaking Biology Technology:Bayer HealthCare Expands Collaboration with Broad Institute of MIT and Harvard to Develop Therapies for Cardiovascular Disease 2Bayer HealthCare Expands Collaboration with Broad Institute of MIT and Harvard to Develop Therapies for Cardiovascular Disease 3Sight Restoration Through Stem Cell Therapy - Subject of June Symposium of Experts 2PMG Research announces formation of VaxCorps with two industry-leading vaccine site networks 2Yale University and Novogen Release Data on Cantrixil Mode of Action 2Yale University and Novogen Release Data on Cantrixil Mode of Action 3Yale University and Novogen Release Data on Cantrixil Mode of Action 4
    ... health officials may not be saying it, but they are ... the deadly avian flu virus begins quietly in scattered areas ... handle on it - with substantial harm done to public ... and one that is exacerbated by the lack of an ...
    ... - Last Sunday morning, in the free-wheeling environment ... shared secrets and strategies from her forthcoming book, titled ... she expects to publish next year. , ,In her ... Huber provided advice about maximizing efficiency and minimizing hurt ...
    ... including one from California, to stem cell patents held ... lack merit and underscore the need for serious patent ... of challenging patents, such as those held by WARF, ... the United States Patent and Trademark Office ...
    Cached Biology Technology:UW compound counters Avian flu 2UW compound counters Avian flu 3BarCamp talk turns to Internet dating 2BarCamp talk turns to Internet dating 3WARF challenges show need for patent reform 2WARF challenges show need for patent reform 3WARF challenges show need for patent reform 4
    (Date:3/16/2015)... , March 16, 2015 ... Systems GmbH will present groundbreaking innovations in biometric ... Hanover, Germany .      (Photo: ... latest biometric innovation is well at the forefront: ... generation e-gate made in Germany ...
    (Date:3/12/2015)... , March 12, 2015 WHEN:Tuesday, March ... Registration here: http://bit.ly/1G7Os0L . SPEAKERS: , Frost ... SeshagiriPhoto - http://photos.prnewswire.com/prnh/20150311/181111 Biometric ... to compete in several different markets and industries. ... currently witnessing an uptrend. Join ...
    (Date:3/10/2015)... , March 10, 2015 ... "Personalized Medicine in Human Space Flight" ... Thomas J. Goodwin , Ph.D. was recently featured ... the past two years. Specifically, "Personalized Medicine ... downloaded scientific papers published in 2013 and 2014 from ...
    Breaking Biology News(10 mins):DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 2DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 3Biometrics Key to Future Growth in Healthcare, Retail and Financial Markets 2Biometrics Key to Future Growth in Healthcare, Retail and Financial Markets 3"Personalized Medicine in Human Space Flight" Listed Among Most Influential Papers of 2013 and 2014 2
    ... A retired but well-preserved mechanism for regulating viruses ... appears to modulate a switch between adult and fetal ... That switch could be the key to more targeted ... hinders its ability to deliver oxygen throughout the body. ...
    ... the point of holding a soccer world championship if we ... then again, wouldn,t it be fantastic if your favourite team,s ... motion! Unfortunately, this advantage only belongs to flies. The minute ... fractions of a second. Just how the brain of the ...
    ... While scientists have conducted numerous studies on production of ... yet compiled this information to evaluate the response of biomass ... States. A team of researchers from Oak Ridge National ... the July-August 2010 Agronomy Journal , published by the ...
    Cached Biology News:Modulator of fetal hemoglobin switch may target sickle cell disease 2Modulator of fetal hemoglobin switch may target sickle cell disease 3The brain of the fly -- a high-speed computer 2The brain of the fly -- a high-speed computer 3The brain of the fly -- a high-speed computer 4Yield projections for switchgrass as a biofuel crop 2
    MAb to IgG2 (Fc gamma-2) IgG2 (Fc, gamma-2 epitope)...
    ... Orange G Dye runs faster ... in standard agarose gels.,Orange G dye ... nucleotides long. The migration at this ... bands, and,conveniently indicates the front of ...
    Rabbit anti Xanthine Oxidase Xanthine Oxidase, Bovine Buttermilk...
    ... Kits without ammonium sulfate are compatible with ... as Taq and AmpliThem™™ DNA polymerases. You ... systems in one experiment by adding your ... the PreMixes supplied with the kit. This ...
    Biology Products: